Multiplex Testing: CDRH Guidance Provokes Array Of Industry Comments
This article was originally published in The Gray Sheet
Executive Summary
Abbott Labs is urging CDRH to clarify that its April 1draft guidance on multiplex tests for heritable markers, mutations and expression patterns applies only to device submissions
You may also be interested in...
Proteomics And Genomics Are Forcing A Re-look At Test Validation Protocol
Test developers might need to adjust their approach to assay validation to facilitate adoption of some up-and-coming diagnostic technologies, several speakers suggested at an American Association of Clinical Chemistry meeting Oct. 25 in Washington, D.C
Proteomics And Genomics Are Forcing A Re-look At Test Validation Protocol
Test developers might need to adjust their approach to assay validation to facilitate adoption of some up-and-coming diagnostic technologies, several speakers suggested at an American Association of Clinical Chemistry meeting Oct. 25 in Washington, D.C
FDA Genetic Array Submissions Guidance Dovetails With NCCLS Effort
FDA's guidance on "Pharmacogenetic Tests and Genetic Tests for Heritable Markers," to be issued by year-end, will exclude gene expression arrays, according to the agency